ACHV

Business Context and Reporting Period

Company: OncoGenex Pharmaceuticals, Inc. (Note: Metadata listed "ACHIEVE LIFE SCIENCES, INC." but the filing text confirms the registrant is OncoGenex Pharmaceuticals, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2011
Business Overview: A clinical-stage biopharmaceutical company developing therapies to address treatment resistance in cancer. The company's primary asset is custirsen, developed in collaboration with Teva Pharmaceutical Industries Ltd. Other pipeline candidates include OGX-427, OGX-225, and CSP-9222. The company ceased development efforts for SN2310 in Q1 2011.

Key Financial Metrics

Note: Q1 2010 comparative balance sheet data is not provided in the text, only income and cash flow statements.

Material Changes vs. Prior Period

• Revenue Decline: Collaboration revenue decreased by approximately 74% ($3.5 million) compared to Q1 2010. This was due to lower reimbursement revenue from Teva as manufacturing costs are now paid directly by Teva, and lower clinical trial costs.
• Expense Reduction: Total expenses decreased by $1.3 million. Research and Development (R&D) expenses dropped from $6.4 million to $4.9 million, primarily due to lower custirsen manufacturing costs and clinical trial costs, partially offset by increased costs for OGX-427. General and Administrative (G&A) expenses increased slightly to $1.6 million due to higher employee and stock-based compensation costs.
• Non-Cash Gain: The company recorded a $2.1 million gain on the revaluation of warrant liabilities, which significantly reduced the net loss for the period despite a similar operating loss to the prior year.
• Liquidity Position: Cash and cash equivalents decreased significantly from $23.5 million at year-end 2010 to $7.0 million at March 31, 2011. However, short-term investments increased to $74.1 million, resulting in total liquid assets of approximately $81.1 million.

Guidance, Outlook, and Risks

• Capital Resources: Management believes current capital resources (cash, equivalents, and short-term investments) are sufficient to fund planned operations into 2014. This includes completing three Phase 3 trials for custirsen and Phase 2 trials for OGX-427.
• Collaboration Obligations: OncoGenex has a remaining funding commitment of $21.0 million toward the custirsen Clinical Development Plan. Teva funds all other expenses. The company expects to incur all remaining costs by Q4 2012.
• Clinical Pipeline:
  • Custirsen: Two Phase 3 trials (SATURN and SYNERGY) are ongoing for prostate cancer. A third Phase 3 trial for non-small cell lung cancer (NSCLC) is expected to initiate in 2011.
  • OGX-427: Phase 2 trials in prostate cancer and bladder cancer are planned or ongoing.
• Key Risks:
  • Dependence on Teva: Success is heavily reliant on Teva's commitment and performance. Termination of the agreement could leave OncoGenex responsible for remaining trial costs.
  • Clinical Trial Uncertainty: Failure of Phase 3 trials to demonstrate efficacy or safety would prevent regulatory approval and commercialization.
  • Intellectual Property: Reliance on third-party licensors (UBC, Isis, Bayer) for patent rights; disputes or expiration could impact commercial viability.
  • Manufacturing: Reliance on third-party contract manufacturers; quality issues or capacity constraints could delay trials.

Investor Verification Checklist

• Collaboration Agreement Status: Verify the current status of the Teva collaboration and any potential risks of termination or change in funding responsibilities.
• Cash Runway: Confirm the accuracy of the projection that current liquid assets ($81.1 million) will sustain operations through 2014, considering the $21 million remaining funding commitment.
• Clinical Trial Progress: Monitor enrollment and interim data for the SATURN and SYNERGY Phase 3 trials, as well as the initiation of the NSCLC trial.
• Warrant Liability: Understand the volatility of the warrant liability valuation (Level 3 fair value) and its impact on reported net income/loss.
• Third-Party Royalties: Review the potential obligation to pay 30% of milestone payments to Isis Pharmaceuticals, as there is a disagreement regarding the classification of certain payments.